Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 17, 2021 - Issue 8
Submit an article Journal homepage
3,081
Views
22
CrossRef citations to date
0
Altmetric
Short Report

Early examination of real-world uptake and second-dose completion of recombinant zoster vaccine in the United States from October 2017 to September 2019

Brandon J. Pattersona US Health Outcomes & Epidemiology, GSK, Philadelphia, PA, USA [Employment at Initial Submission]Correspondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-5319-9493View further author information
ORCID Icon,
Chi-Chang Chenb IQVIA, Pennsylvania, PA, USAORCID Iconhttps://orcid.org/0000-0002-7065-9607View further author information
ORCID Icon,
Catherine B. McGuinessb IQVIA, Pennsylvania, PA, USAORCID Iconhttps://orcid.org/0000-0002-5367-6472View further author information
ORCID Icon,
Lisa I. Glassera US Health Outcomes & Epidemiology, GSK, Philadelphia, PA, USA [Employment at Initial Submission]ORCID Iconhttps://orcid.org/0000-0002-9863-7098View further author information
ORCID Icon,
Kainan Sunb IQVIA, Pennsylvania, PA, USAORCID Iconhttps://orcid.org/0000-0001-7084-7512View further author information
ORCID Icon &
Philip O. Bucka US Health Outcomes & Epidemiology, GSK, Philadelphia, PA, USA [Employment at Initial Submission]ORCID Iconhttps://orcid.org/0000-0002-3898-3669View further author information
ORCID Icon
Pages 2482-2487 | Received 07 Oct 2020, Accepted 13 Jan 2021, Published online: 13 Apr 2021

Citations (22)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Raunak Parikh, David Singer, Elizabeth Chmielewski-Yee & Christophe Dessart. (2023) Effectiveness and safety of recombinant zoster vaccine: A review of real-world evidence. Human Vaccines & Immunotherapeutics 19:3.
Read now
Paul K. S. Chan, Martin C. S. Wong, Macy Chan, Karen Ching, Nikolaos Giannelos & Cheryl Ng. (2023) Public health impact of herpes zoster vaccination on older adults in Hong Kong. Human Vaccines & Immunotherapeutics 19:1.
Read now
Marta Ulaszewska, Sarah Merelie, Sarah Sebastian & Teresa Lambe. (2023) Preclinical immunogenicity of an adenovirus-vectored vaccine for herpes zoster. Human Vaccines & Immunotherapeutics 19:1.
Read now
Desmond Curran, Elizabeth M. La, Ahmed Salem, David Singer, Nicolas Lecrenier & Sara Poston. (2022) Modeled impact of the COVID-19 pandemic and associated reduction in adult vaccinations on herpes zoster in the United States. Human Vaccines & Immunotherapeutics 18:1.
Read now

Articles from other publishers (18)

Desmond Curran, Desirée Van Oorschot, Sean Matthews, Johannes Hain, Ahmed Ehab Salem & Magdalena Schwarz. (2021) Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany. Human Vaccines & Immunotherapeutics 17:12, pages 5296-5303.
Crossref
Lawrence Petherbridge, Charlotte Davis, Angela Robinson, Thomas Evans & Sarah Sebastian. (2023) Pre-Clinical Development of an Adenovirus Vector Based RSV and Shingles Vaccine Candidate. Vaccines 11:11, pages 1679.
Crossref
Stanley Xu, Vennis Hong, Lina S Sy, Katia J Bruxvoort, Bruno Lewin, Bing Han, Kimberly J Holmquist & Lei Qian. (2023) Risk Factors for Not Completing a 2-Dose Primary Series of Messenger RNA COVID-19 Vaccination in a Large Health Care System in Southern California: Retrospective Cohort Study. JMIR Public Health and Surveillance 9, pages e46318.
Crossref
David Singer, Ahmed Salem, Nikita Stempniewicz, Siyu Ma, Sara Poston & Desmond Curran. (2023) The potential impact of increased recombinant zoster vaccine coverage on the burden of herpes zoster among adults aged 50–59 years. Vaccine 41:37, pages 5360-5367.
Crossref
Erin Roberts-McCarthy, Philip O. Buck, Renae L. Smith-Ray, Nicolas Van de Velde, Tanya Singh, James Mansi, Amy Shah & Michael Taitel. (2023) Factors associated with receipt of mRNA-1273 vaccine at a United States national retail pharmacy during the COVID-19 pandemic. Vaccine 41:29, pages 4257-4266.
Crossref
Justin Gatwood, Andrea Brookhart, Olivia Kinney, Tracy Hagemann, Chi-Yang Chiu, Sujith Ramachandran, Emily Gravlee & Kenneth Hohmeier. (2023) Impact of patient and provider nudges on addressing herpes zoster vaccine series completion. Vaccine 41:3, pages 778-786.
Crossref
Binshan Jiang, Qing Wang, Zhenzhong Wang, Yunshao Xu, Tao Yang, Weizhong Yang, Mengmeng Jia & Luzhao Feng. (2022) Willingness to accept herpes zoster vaccines and the influencing factors in China. BMC Infectious Diseases 22:1.
Crossref
Jean-Etienne Poirrier, Juliana L. Meyers, Saurabh P. Nagar, Brandon J. Patterson, Lisa I. Glasser & Serge A. Jabbour. (2022) Herpes Zoster Incidence and Burden in Adults With Type 2 Diabetes in the U.S.: A Retrospective Database Analysis. Diabetes Care 45:11, pages 2585-2593.
Crossref
Angela R. Wateska, Mary Patricia Nowalk, Chyongchiou J. Lin, Lee H. Harrison, William Schaffner, Richard K. Zimmerman & Kenneth J. Smith. (2022) Cost-effectiveness of revised US pneumococcal vaccination recommendations in underserved minority adults < 65-years-old. Vaccine 40:50, pages 7312-7320.
Crossref
Jessica Leung, Elizabeth B. Gray, Tara C. Anderson, Sarah M. Sharkey & Kathleen Dooling. (2022) Recombinant zoster vaccine (RZV) second-dose series completion in adults aged 50–64 years in the United States. Vaccine 40:50, pages 7187-7190.
Crossref
Jessica Leung, Tara C. Anderson, Kathleen Dooling, Fenglong Xie & Jeffrey R. Curtis. (2022) Recombinant Zoster Vaccine Uptake and Risk of Flares Among Older Adults With Immune‐Mediated Inflammatory Diseases in the US. Arthritis & Rheumatology 74:11, pages 1833-1841.
Crossref
Justin Gatwood, Andrea Brookhart, Olivia Kinney, Tracy Hagemann, Chi-Yang Chiu, Sujith Ramachandran & Kenneth C. Hohmeier. (2022) Clinical Nudge Impact on Herpes Zoster Vaccine Series Completion in Pharmacies. American Journal of Preventive Medicine 63:4, pages 582-591.
Crossref
Jamison Pike, Andrew J. Leidner, Harrell Chesson, Charles Stoecker & Scott D. Grosse. (2022) Data-Related Challenges in Cost-Effectiveness Analyses of Vaccines. Applied Health Economics and Health Policy 20:4, pages 457-465.
Crossref
Lida Teng, Akiko Mizukami, Cheryl Ng, Nikolaos Giannelos, Desmond Curran, Tomohide Sato, Christa Lee & Taizo Matsuki. (2022) Cost-Effectiveness Analysis Update of the Adjuvanted Recombinant Zoster Vaccine in Japanese Older Adults. Dermatology and Therapy 12:6, pages 1447-1467.
Crossref
Megan G. Lloyd, Michael B. Yee, Joseph S. Flot, Dongmei Liu, Brittany W. Geiler, Paul R. Kinchington & Jennifer F. Moffat. (2022) Development of Robust Varicella Zoster Virus Luciferase Reporter Viruses for In Vivo Monitoring of Virus Growth and Its Antiviral Inhibition in Culture, Skin, and Humanized Mice. Viruses 14:4, pages 826.
Crossref
Joyce LaMori, Xue Feng, Christopher D Pericone, Marco Mesa-Frias, Obiageli Sogbetun & Andrzej Kulczycki. (2022) Real-world evidence on adherence and completion of the two-dose recombinant zoster vaccine and associated factors in U.S. adults, 2017–2021. Vaccine 40:15, pages 2266-2273.
Crossref
Brandon J. Patterson, Chi-Chang Chen, Catherine B. McGuiness, Siyu Ma, Lisa I. Glasser, Kainan Sun & Philip O. Buck. (2022) Factors influencing series completion rates of recombinant herpes zoster vaccine in the United States: A retrospective pharmacy and medical claims analysis. Journal of the American Pharmacists Association 62:2, pages 526-536.e10.
Crossref
Birgit Weinberger. 2022. Healthy Longevity and Immune System. Healthy Longevity and Immune System 119 164 .

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.